ReviewMolecular neurodegeneration advances2026
Autophagy-lysosomal pathway in neurodegeneration.
Review in Molecular neurodegeneration advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Autophagy-Lysosomal Pathway (ALP) dysfunction has emerged as a prominent mechanism underlying neurodegenerative disease. Given its central role in facilitating cellular clearance of misfolded proteins, damaged organelles and other cellular debris, the ALP is vital for cellular health and survival. In mature neurons, whose post-mitotic state renders them unable to dilute such materials through cell division, this waste removal pathway takes on an even greater importance. It is therefore unsurprising that ALP dysfunction is increasingly implicated in the context of age-associated neurodegenerative disease, where impaired proteostasis and pathological protein aggregation are common hallmarks. The focus of this review is how dysregulation of ALP-associated processes, including autophagic flux, chaperone-mediated autophagy, endolysosomal trafficking, lysosomal pH and ion balance, and lysosomal metabolic signaling, is implicated in both the pathogenesis and progression of neurodegenerative diseases, with an emphasis on Alzheimer's disease and Parkinson's disease. A more detailed understanding of how these processes, both independently and cooperatively, contribute to the development and progression of neurodegenerative disease will improve our understanding of these debilitating disorders and inform the development of ALP-targeted therapeutic strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.